Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P60604
UPID:
UB2G2_HUMAN
Alternative names:
E2 ubiquitin-conjugating enzyme G2; Ubiquitin carrier protein G2; Ubiquitin-protein ligase G2
Alternative UPACC:
P60604; A6NMQ7; A8K3L4; D3DSL7; P56554
Background:
Ubiquitin-conjugating enzyme E2 G2, also known as E2 ubiquitin-conjugating enzyme G2, plays a pivotal role in protein ubiquitination, a critical process for protein degradation and regulation. It accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to target proteins, facilitating 'Lys-48'-linked polyubiquitination. This enzyme is essential for the endoplasmic reticulum-associated degradation (ERAD) pathway and is involved in the sterol-induced ubiquitination and subsequent degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Therapeutic significance:
Understanding the role of Ubiquitin-conjugating enzyme E2 G2 could open doors to potential therapeutic strategies, particularly in diseases where protein degradation and regulation are compromised.